<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161833</url>
  </required_header>
  <id_info>
    <org_study_id>OPERA2</org_study_id>
    <nct_id>NCT04161833</nct_id>
  </id_info>
  <brief_title>Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA)</brief_title>
  <acronym>AIA</acronym>
  <official_title>Use of an Alfa-lipoic, Methylsulfonylmethane and Bromelain Dietary Supplement (Opera®) for Aromatase Inhibitor-related Arthralgia Management (AIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Careggi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase II, multicenter, self-controlled clinical trial, we will evaluate the safety&#xD;
      and efficacy of OPERA® for treating anti-aromate inhibitors (AIs) induced arthralgia. The&#xD;
      diagnosis of arthralgia will be based on the NCI-CTCAE v4.0 grade of ≥ 1 , A disorder&#xD;
      characterized by a sensation of marked discomfort in a joint, mild pain (grade 1). Arthralgia&#xD;
      will be assessed at the enrollment and every two months until the sixth month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aromatase Inhibitors (AIs) are recommended for the adjuvant treatment of hormone receptor&#xD;
      positive breast cancers in the post-menopausal population. Compared with Tamoxifen, third&#xD;
      generation aromatase inhibitors have been shown to significantly improve disease free&#xD;
      survival (DFS), and include the steroidal inhibitor exemestane, and the nonsteroidal&#xD;
      inhibitors, anastrozole and letrozole. Although the AIs are associated with fewer&#xD;
      thromboembolic events and endometrial abnormalities than is tamoxifen, approximately 25% of&#xD;
      postmenopausal women on AI report arthralgia, skeletal, and muscle pain. The multicentre&#xD;
      double-blind placebo-controlled ma.17 trial by the National Cancer Institute of Canada&#xD;
      Clinical Trials Group revealed marked increases in arthralgia (25% vs. 21%) and myalgia (15%&#xD;
      vs. 12%) in patients on letrozole as compared with those on placebo. The Intergroup&#xD;
      Exemestane Study shown a link between arthralgia and the ai exemestane (5.4% exemestane vs.&#xD;
      3.6% tamoxifen).The Arimidex, Tamoxifen Alone or in Combination (atac) trial, after 68&#xD;
      months' median follow-up, showed that the incidence of arthralgia was significantly higher in&#xD;
      the anastrozole group than in the tamoxifen group [1100 of 3092 (35.6%) vs. 911 of 3094&#xD;
      (29.4%) patients]. Currently, evidences of drugs efficacy to reduce these side effects are&#xD;
      sparse.OPERA® (GAMFARMA srl, Milan, Italy) is a new dietary supplement where α-Lipoic acid&#xD;
      (240mg), BS (40mg), MSM (200mg) and Bromelain (20mg) are combined together in a single&#xD;
      hard-gelatin capsule. The aim of this prospective study is to determine the efficacy and&#xD;
      safety of OPERA® supplementation in a series of patients affected by arthralgia during AI&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of AI induced arthralgia at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of AI-induced arthralgia assessed with VAS scale (0, no pain, to 5, worst pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of AI induced arthralgia at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of AI-induced arthralgia assessed with PRAI questionnaire (16 items that query pain severity over the last 7 days in eight joints using a rating scale of 0-10, with 10 being greatest severity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life assessed with FACT-ES questionnaire (19 items which assess endocrine complaints and adverse effects with response scores ranging from 0 to 4 ('not at all', 'a little bit', 'somewhat', 'quite a bit', and 'very much.')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Compliance to AI therapy (percentage of patients that have not discontinued and/or changed originally prescribed anti-aromatase inhibitor)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hormone Receptor Positive Tumor</condition>
  <condition>Arthralgia</condition>
  <arm_group>
    <arm_group_label>OPERA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women receiving adjuvant aromates-inhibitor with arhtralgia grade ≥ 1 (CTACAE 4.03)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OPERA</intervention_name>
    <description>All patients were required to take an OPERA® capsule (dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule) once daily,from enrollment up to sixth months.</description>
    <arm_group_label>OPERA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Karnofsky performance score≥70&#xD;
&#xD;
          -  Indication for AI treatment in adjuvant setting for breast cancer&#xD;
&#xD;
          -  Arthralgia with grade ≥0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant diseases, e.g. diabetes, renal insufficiency, alcohol abuse&#xD;
&#xD;
          -  Concomitant rheumatological disease (Rheumatoid arthritis, Spondyloarthropathies,&#xD;
             Psoriatic arthritis, etc.)&#xD;
&#xD;
          -  Concomitant endocrinological disease (Acromegaly , Emocromatosis, etc)&#xD;
&#xD;
          -  Any conditions that would complicate arthralgia assessment (e.g. Trauma,&#xD;
             Glucocorticoid withdrawal, Hypertrophic osteoarthropathy, Osteoarthritis, Avascular&#xD;
             necrosis, Gout, Systemic lupus erythematosus, Septic arthritis, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isacco Desideri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Oncology Unit, AOU Careggi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorenzo Livi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radiation Oncology Unit, AOU Careggi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria Careggi</investigator_affiliation>
    <investigator_full_name>Lorenzo Livi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>luminal tumor</keyword>
  <keyword>anti-aromatase inhibitors</keyword>
  <keyword>arthralgia</keyword>
  <keyword>dietary supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

